Skip to main content

bdc-1001

bdc-1001: 2 clinical trials tracked.

bdc-1001 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bdc-1001, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (2)

Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan

NCT05954143Registry updated 2025-11-20·Phase 2·BOLT
Terminated

Primary endpoint: Objective Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigator

InterventionalRandomizedopen11 targetStarted 2023-11Completion 2024-094 sites · Spain, United StatesBolt Biotherapeutics, Inc.

Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors

NCT04278144Registry updated 2025-09-15·Phase 1/Phase 2·BOLT
Terminated

Primary endpoint: Incidence of adverse events (AEs) and serious adverse events (SAEs)

Interventionalopen175 targetStarted 2020-02Completion 2025-0221 sites · France, South Korea, Spain, United StatesBolt Biotherapeutics, Inc.